A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale

Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I–III clinical trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer. Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologo...

Descripción completa

Detalles Bibliográficos
Autores principales: Isakoff, Steven J, Puhalla, Shannon, Domchek, Susan M, Friedlander, Michael, Kaufman, Bella, Robson, Mark, Telli, Melinda L, Diéras, Véronique, Han, Hyo Sook, Garber, Judy E, Johnson, Eric F, Maag, David, Qin, Qin, Giranda, Vincent L, Shepherd, Stacie P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2017
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618936/
https://www.ncbi.nlm.nih.gov/pubmed/27739325
http://dx.doi.org/10.2217/fon-2016-0412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618936/
https://www.ncbi.nlm.nih.gov/pubmed/27739325
http://dx.doi.org/10.2217/fon-2016-0412

Ejemplares similares